Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H30O5 |
Molecular Weight | 374.4706 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])C[C@H](C)C4=CC(=O)C=C[C@]34C
InChI
InChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1
Molecular Formula | C22H30O5 |
Molecular Weight | 374.4706 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00959Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html
Sources: http://www.drugbank.ca/drugs/DB00959
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/medrol.html
Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800003722
Curator's Comment: # Pfizer
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00959 |
2.4 nM [EC50] | ||
Target ID: CHEMBL2034 Sources: http://www.ampoule.org.hk/pdf/advantan.pdf |
|||
Target ID: CHEMBL2111332 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15329590 |
1.07 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date-3.84739213E11 |
|||
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date-3.84739213E11 |
|||
Primary | MEDROL Approved UseINDICATIONS AND USAGE
MEDROL Tablets are indicated in the following conditions:
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Synovitis of osteoarthritis
Acute nonspecific tenosynovitis
Post-traumatic osteoarthritis
Psoriatic arthritis
Epicondylitis
Acute gouty arthritis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Acute rheumatic carditis
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Severe seborrheic dermatitis
Exfoliative dermatitis
Mycosis fungoides
Pemphigus
Severe psoriasis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Contact dermatitis
Bronchial asthma
Atopic dermatitis
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Sympathetic ophthalmia
Keratitis
Optic neuritis
Allergic conjunctivitis
Chorioretinitis
Iritis and iridocyclitis
7. Respiratory Diseases
Symptomatic sarcoidosis
Berylliosis
Loeffler's syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy
Aspiration pneumonitis
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of:
Leukemias and lymphomas in adults
Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in:
Ulcerative colitis
Regional enteritis
12. Nervous System
Acute exacerbations of multiple sclerosis
13. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
Trichinosis with neurologic or myocardial involvement. Launch Date-3.84739213E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
213 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
931 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/12174030 |
32 mg single, intravenous dose: 32 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23% |
METHYLPREDNISOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1000 mg/kg single, intravenous Highest studied dose Dose: 1000 mg/kg Route: intravenous Route: single Dose: 1000 mg/kg Sources: |
unhealthy, 0-15 years n = 26 Health Status: unhealthy Condition: sickle cell disease Age Group: 0-15 years Sex: M+F Population Size: 26 Sources: |
|
1250 mg 1 times / day multiple, oral Highest studied dose Dose: 1250 mg, 1 times / day Route: oral Route: multiple Dose: 1250 mg, 1 times / day Sources: |
unhealthy, 18–59 years n = 24 Health Status: unhealthy Condition: multiple sclerosis relapse Age Group: 18–59 years Sex: M+F Population Size: 24 Sources: |
|
120 mg 1 times / week multiple, intramuscular Highest studied dose Dose: 120 mg, 1 times / week Route: intramuscular Route: multiple Dose: 120 mg, 1 times / week Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubs.acs.org/doi/abs/10.1021/mp900163d Page: - |
no | |||
Page: - |
yes | |||
Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
yes | |||
Page: - |
yes | |||
Sources: http://epubs.surrey.ac.uk/855783/1/27606608.pdf Page: - |
yes | |||
Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
[A senile case of acute necrotizing myopathy presenting prolonged severe muscle paralysis due to high dose glucocorticoid and muscle relaxant]. | 2000 Mar |
|
High-dose methylprednisolone may do more harm for spinal cord injury. | 2000 Nov |
|
Methylprednisolone concentrations in the vitreous and the serum after pulse therapy. | 2001 |
|
Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome. | 2001 Apr |
|
Lupus nephritis in a child with AIDS. | 2001 Apr |
|
Severe renal impairment in the case of classic polyarteritis nodosa. | 2001 Feb |
|
Three cases of C-ANCA-positive vasculitis treated with immunoadsorption: possible benefit in early treatment. | 2001 Feb |
|
Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. | 2001 Feb |
|
Selective involvement of the choroid plexus on cerebral magnetic resonance images: a new radiological sign in patients with systemic lupus erythematosus with neurological symptoms. | 2001 Feb |
|
Effects of intraarticular glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: findings in a double-blind, placebo-controlled study. | 2001 Feb |
|
Glucocorticoid inhibition of neuropathic hyperalgesia and spinal Fos expression. | 2001 Feb |
|
Preliminary results of a prospective randomized study of basiliximab in kidney transplantation. | 2001 Feb-Mar |
|
Standard cyclosporine A-based versus completely steroid-free FK506-based immunosuppression after liver transplantation. | 2001 Feb-Mar |
|
Prevention of bone loss in kidney graft recipients. | 2001 Feb-Mar |
|
Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. | 2001 Feb-Mar |
|
Graft failure in a patient with systemic lupus erythematosus (SLE) treated with high-dose immunosuppression and autologous stem cell rescue. | 2001 Jan |
|
A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease. | 2001 Jan |
|
[Severe chronic actinic dermatitis treated with cyclosporine: 2 cases]. | 2001 Jan |
|
Preventive effects of lecithinized superoxide dismutase and methylprednisolone on spinal cord injury in rats: transcriptional regulation of inflammatory and neurotrophic genes. | 2001 Jan |
|
New treatment for postherpetic neuralgia. | 2001 Jan |
|
Methylprednisolone ameliorates cochlear nerve degeneration following mechanical injury. | 2001 Jan |
|
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. | 2001 Jan |
|
Management of cutaneous hemangiomas: a retrospective analysis of 1109 cases and comparison of conventional dose prednisolone with high-dose methylprednisolone therapy. | 2001 Jan-Feb |
|
[Acute myelitis of an unusual cause in a child: the lymphocytic choriomeningitis virus]. | 2001 Mar |
|
Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. | 2001 Mar |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
Intrathecal methylprednisolone for postherpetic neuralgia. | 2001 Mar 29 |
|
[Comparison of two different treatments of lateral humeral epicondylitis--"tennis elbow". A randomized controlled trial]. | 2001 Mar 5 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/medrol.html
Each Medrol Tablet (methylprednisolone) for oral administration contains 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of methylprednisolone. The initial dosage of Medrol Tablets may vary from 4 mg to 48 mg of methylprednisolone per day depending on the specific disease entity being treated.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26339357
Treatment with methylprednisolone concentrations above 50 uM could ignificantly reduce the proliferation activity of human CLL cell line MEC-1 by 23.34%, 30.73%, 30.57% after 24 h, and 28.48%, 42.35%, 44.56% after 48 h respectively
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:06:46 UTC 2023
by
admin
on
Fri Dec 15 15:06:46 UTC 2023
|
Record UNII |
X4W7ZR7023
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QH02AB04
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
FDA ORPHAN DRUG |
531816
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ATC |
S01CA08
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
CFR |
21 CFR 520.1408
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ATC |
D07AA01
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
CFR |
21 CFR 520.1409
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-VATC |
QD07CA02
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-VATC |
QH02BX01
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
CFR |
21 CFR 522.1410
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ATC |
H02BX01
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-VATC |
QS01CA08
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ATC |
D07CA02
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ATC |
D07AC14
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-VATC |
QD10AA02
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-VATC |
QD07AA01
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.3
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ATC |
H02AB04
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
NDF-RT |
N0000175450
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
WHO-ATC |
D10AA02
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
||
|
LIVERTOX |
626
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1768
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
D008775
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
C647
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
DB00959
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
100000091803
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
3127
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
83-43-2
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
732
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
6741
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
7088
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
DTXSID7023300
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
6902
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | RxNorm | ||
|
19987
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
SUB08872MIG
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
Methylprednisolone
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
X4W7ZR7023
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
201-476-4
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
6888
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
CHEMBL650
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
X4W7ZR7023
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
METHYLPREDNISOLONE
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
1435003
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
135864
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | |||
|
m7454
Created by
admin on Fri Dec 15 15:06:46 UTC 2023 , Edited by admin on Fri Dec 15 15:06:46 UTC 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
||
|
METABOLITE -> PARENT |
MAJOR
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||